TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01590966
Drug: administration of Cimzia®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with prefilled syringes containing each 200 mg/ml Cimzia® every 2 weeks which will be administered subcutaneously (The first 3 injections, a dosage of 400mg Cimzia® subcutaneously will be administered).
Study: NCT01590966
Drug: Immunoscintigraphy with radiolabeled Cimzia®.
Approvals — FDA: no, EMA: no, PMDA: no
Description: All 20 patients will undergo an immunoscintigraphy with radiolabeled Cimzia®. Certolizumab pegol (Cimzia®) is an engineered humanized monoclonal antibody Fab' fragment with specificity for human TNF-α, manufactured in E. coli. The antibody fragment is subsequently purified and conjugated with high molecular weight polyethylene glycol (PEG) (40kDa). Lyophilized Cimzia® will be conjugated with S-HYNIC (a bifunctional chelator). The conjugate will be radiolabeled with Tc-99m by adding 0.1 mg Tricine, 0.01 mg SnSO4 and 750 MBq Tc-99m pertechnetate. A dose of 750 MBq Tc-99m Cimzia® will be injected intravenously.
Study: NCT00249041
Drug: Enbrel liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg Etanercept liquid injected SC once weekly using prefilled syringes
Study: NCT00211939
Drug: calcium acetate
Normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 667 mg gelcap, 2-4 t.i.d titrated to serum phosphorus level
Study: NCT03561740
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: additional metronomic chemotherapy of capecitabine
Study: NCT01058824
Drug: Lincomycin
Normalized name: Lincomycin
DrugBank: Lincomycin (DB01627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single Dose Hard Gelatin Capsule - oral - 500 mg
Study: NCT00421733
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 - Placebo once daily (two placebo capsules once daily)
Study: NCT00712049
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin 40 mg
Study: NCT00676052
Drug: GSK233705 12.5mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily via dry powder inhaler
Study: NCT00676052
Drug: GSK233705 25mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily via dry powder inhaler
Study: NCT00676052
Drug: GSK233705 50mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily via dry powder inhaler
Study: NCT00676052
Drug: GSK233705 100mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily via dry powder inhaler
Study: NCT00676052
Drug: GSK233705 200mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily via dry powder inhaler
Study: NCT00676052
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily via dry powder imhaler
Study: NCT02587364
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily (QD)
Study: NCT00407030
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04243837
Drug: Placebo BCRL
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCRL patients will receive Placebo BID for 6 months
Study: NCT02200445
Drug: Interleukin-2 (aldesleukin).
Approvals — FDA: no, EMA: no, PMDA: no
Description: Description of intervention is covered in Arm, above.
Study: NCT00066170
Drug: Xyrem Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xyrem Placebo oral solution 12 ml per day for 4 weeks and 18 ml per day for another 4 weeks.
Study: NCT01049672
Drug: Diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated to a maximum dose of 500mg in 24 hours given subcutaneously
Study: NCT00769405
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00769405
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02524678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02524678
Drug: URC102
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00430859
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline over a period of 24h
Study: NCT00106535
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV/month
Study: NCT00106535
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-25 mg/week
Study: NCT02072993
Drug: AZD1979
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, oral solution administration
Study: NCT02072993
Drug: Placebo to match
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, oral solution administration
Study: NCT02945046
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to fremanezumab will be administered per schedule specified in the arm.
Study: NCT01194700
Drug: Seretide 250 (8 puffs)/placebo via Volumatic spacer
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 puffs of Seretide 250/placebo via volumatic spacer
Study: NCT01194700
Drug: Seretide 250/placebo via Synchro-Breathe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seretide 250/placebo 8puffs via breath actuated Synchro-Breathe device
Study: NCT01738178
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01738178
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02838238
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02838238
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03985995
Drug: CBD 800 mg p.o
Approvals — FDA: no, EMA: no, PMDA: no
Description: cannabidiol solution 100 mg/ml 8 ml in single-dose containers for per os administration. After a washout period of at least two weeks, the treatment group will be receiving a single-dose of the placebo solution 8 ml as a second intervention.
Study: NCT03985995
Drug: Placebo p.o
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of oral placebo solution 8 ml matched to the IMP. After a washout period of at least two weeks, the control intervention group will be receiving the cannabidiol solution 100 mg/ml 8 ml as a second intervention.
Study: NCT01252940
Drug: FTC/RPV/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily (QD)
Study: NCT01252940
Drug: RTV
Normalized name: Accu-Chek SmartView Test Strips
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (RTV) was administered according to prescribing information.
Study: NCT01252940
Drug: NRTIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRTIs included abacavir, emtricitabine, Combivir (lamivudine/zidovudine, coformulated), Epzicom (abacavir/lamivudine, coformulated), lamivudine, stavudine, tenofovir DF, Truvada® (emtricitabine/tenofovir DF, coformulated), and zidovudine. NRTIs were administered according to prescribing information.
Study: NCT00001339
Drug: doxorubicin, vincristine, and etoposide with mitotane
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00001596
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 pills), three times daily.
Study: NCT00593255
Drug: soluble human insulin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00593255
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01113957
Drug: pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B subjects randomized to pegylated liposomal doxorubicin on Day 1, every 28 days intravenously.
Study: NCT03432689
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule matched to cycloserine capsule
Study: NCT04774874
Drug: Topical formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration on the scalp once daily for 16 weeks
Study: NCT00074087
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00463346
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01572909
Drug: Bendavia (MTP-131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg/hr
Study: NCT01572909
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identically appearing placebo
Study: NCT03259308
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 1 mL of sterile aqueous buffered solution.
Study: NCT00996177
Drug: IONSYS (fentanyl HCl) Iontophoretic TransdermalSystem
Normalized name: fentanyl Transdermal System [Ionsys]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 µg fentanyl on-demand (240µg/hr) or a maximum of 80 doses (3.2 mg) per day
Study: NCT02455180
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive vitamin C 4 times in either high (5g) or moderate (1g) dose. Vitamin C will be administered intravenously (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands) in 50ml of NaCl 0.9%, infused over 30 minutes.
Study: NCT04324489
Drug: DAS181
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient receives nebulized DAS181 (4.5 mg BID/day, a total 9 mg/day) for 10 days.
Study: NCT04701320
Drug: Conventional glass ionomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glass ionomer with enhanced mechanical and esthetic proberties
Study: NCT04701320
Drug: Nano hydroxyapatite reinforced glass ionomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanohydroxyapatite reinforced glass ionomer restorative material with enhanced mechanical proberties and chemical adhesion to tooth structure
Study: NCT00105508
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo matched to sarizotan orally twice daily for 24 weeks.
Study: NCT04607382
Drug: NSAIDs and/or Chinese medicine (CM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Chinese medicine (CM) dosage up to the discretion of the treating gynecologists.
Study: NCT00922389
Drug: Standard Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any thing directed to improve blood perfusion in the limb example.Heparin,Antiplatelet agents etc
Study: NCT00003474
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adults with a residual/recurrent/progressive Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT03123107
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid doses will be mixed in 100 mL normal saline and infused over 60 minutes. The postoperative dose will be given on postoperative day #1.
Study: NCT03158311
Drug: QVM149
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol acetate / glycopyrronium bromide / mometasone furoate
Study: NCT01018953
Drug: BIM 23A760
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIM 23A760 is a solution at a concentration of 5 mg/mL ready for subcutaneous injection. BIM 23A760 dose of 1, 2, 4, 6 and 8 mg can be given to the patient according to a dose escalation and titration process. Patients will receive 24 weekly injections of BIM 23A760 during the treatment period. Patients eligible to continue the extension phase will be administered BIM 23A760 for further 52 weekly injections.
Study: NCT03927716
Drug: SB206 12%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topically once daily
Study: NCT03927716
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topically once daily
Study: NCT03853200
Drug: QMix Root Canal Irrigant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endodontic irrigant recommended for final irrigation
Study: NCT04483947
Drug: AZD2693
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of AZD2693 multiple ascending doses in participants with NASH and who are carriers of the PNPLA3 148M risk allele(s).
Study: NCT02416271
Drug: Placebo-Oral
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02416271
Drug: Placebo-SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT02857959
Drug: Benzathine Penicillin G
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01075204
Drug: clarithromycin modified release 500 mg
Normalized name: clarithromycin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: clarithromycin modified release 500 mg for 7 days
Study: NCT00651807
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every day one tablet up to 8 weeks
Study: NCT04028960
Drug: Regular insulin (Humulin-R), intranasal route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humulin-R insulin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetes.
Study: NCT00954538
Drug: [18F]MK-3328
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV dose of \~150 megabecquerel (MBq) \[18F\]MK-3328
Study: NCT00853047
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching telotristat etiprate capsules; orally 3 times daily.
Study: NCT01164969
Drug: Antibiotics to which H. pylori can not develope resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin, metronidazole and tetracyclin as primary drugs to treat H. pylori infection in duration of 10 days.
Study: NCT02740582
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02149160
Drug: FRM-0334
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02149160
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02113566
Drug: Acetaminophen 1000mg
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects who require rescue medication between hours 4 and 6 will be allowed to take Dose 2 of the study medication. If the subject chooses to take a rescue analgesic (acetaminophen 1000mg), they will be considered a treatment failure. This intervention will be use for the placebo and Ibuprofen arm.
Study: NCT01797185
Drug: SPARC1104 modified dose regimen I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects who exited study CLR_09_21
Study: NCT01797185
Drug: SPARC1104 modified dose regimen II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects who received prior treatment regimen I
Study: NCT01797185
Drug: SPARC1104 modified dose regimen III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects who received no prior treatment regimen
Study: NCT02204462
Drug: FBnTP
Approvals — FDA: no, EMA: no, PMDA: no
Description: A PET imaging radiotracer
Study: NCT02015715
Drug: RO6864018
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral ascending dose of RO6864018 capsules on Day 1.
Study: NCT02015715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of placebo matching RO6864018 capsules on Day 1.
Study: NCT01882621
Drug: Monosialoganglioside(GM1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80mg,ivdrip (in the vein) on day 0 - day 3 of each 21 day cycle. Number of Cycles: 4-6 cycles.
Study: NCT01882621
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80mg,ivdrip(in the vein) on day 0-3 of each 21 day cycle. Number of Cycles: 4-6 cycles.
Study: NCT03407378
Drug: IPT803
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of IPT803 three times a day for 12 weeks as add-on therapy to patient regular PD medication(s) or as a new therapy for drug naïve patients.
Study: NCT02753101
Drug: [18F]-FTC-146
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mCi± 1 mCi of \[18F\]FTC-146 intravenously
Study: NCT01199523
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00688779
Drug: AZD8848
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrate for nasal spray,solution 60 mg/g
Study: NCT00688779
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00994292
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00300586
Drug: observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: observation, second line chemotherapy if progression
Study: NCT04464512
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV buprenorphine plus IV sufentanil treatment group.
Study: NCT01103284
Drug: DiaPep277
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg dose in 0.5 mL of solution
Study: NCT01103284
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg mannitol in 0.5 mL of solution.~Dosing: 0, 1, 3, 6, 9, 12, 15, 18, 21, 24 months
Study: NCT04527250
Drug: ASC41
Normalized name: Ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASC41,1mg/table;5mg/table
Study: NCT04527250
Drug: ASC41 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASC41 placebo,1mg/table;5mg/table
Study: NCT03404167
Drug: AZD0914
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoliflodacin (also known as AZD0914 and ETX0914), is a spiropyrimidinetrione antibacterial agent
Study: NCT00705081
Drug: statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00094627
Drug: Comparator: placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of Treatment - 6 weeks
Study: NCT04370600
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denatonium benzoate + HVMN ketone placebo flavor mix + Stevia
Study: NCT00448357
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg/m\^2 on days +1, +3 and +6
Study: NCT04398914
Drug: Physician's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician decided chemotherapy for 0-4 cycles.
Study: NCT03520569
Drug: Dextrose 20% solution
Normalized name: Dextrose 20% Solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: We are using dextrose to maintain glycemia level
Study: NCT00361244
Drug: SU011248
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally in the morning for two weeks followed by a one week rest period (one cycle equals 21 days). Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
Study: NCT03202550
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral pills
Study: NCT04405388
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given orally as capsule (same size and weight as Spermidine capula)
Study: NCT04405388
Drug: Spermidine
Normalized name: SPERMIDINE
DrugBank: Spermidine (DB03566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spermidine will be given orally as capsule (4mg/day)
Study: NCT04981561
Drug: GATE-251
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of GATE-251
Study: NCT04981561
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03309605
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04162314
Drug: Beta-1,3/1,6-D-Glucan Ganoderma lucidum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-1,3/1,6-D-Glucan capsule three times daily for 90 days
Study: NCT04162314
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos
Study: NCT00394472
Drug: AZD3355
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02201082
Drug: Amikacin nebulization
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00882388
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: celecoxib 200 mg bid \* 7 days
Study: NCT00882388
Drug: aspirin + celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aspirin 100 mg qd + celecoxib 200 mg bid for 7 days
Study: NCT00882388
Drug: aspirin + clopidogrel + celecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin 100 mg qd + clopidogrel 75 mg qd + celecoxib 200 mg bid
Study: NCT03197935
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to atezolizumab was administered as per schedule described in respective arm.
Study: NCT03197935
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin was administered as per schedule described in the arms.
Study: NCT03197935
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide was administered as per schedule described in the arms.
Study: NCT03990688
Drug: AK3280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
Study: NCT03990688
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
Study: NCT01137812
Drug: Sulphonylurea
Normalized name: metformin and sulfonylureas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will continue to take background therapy with Sulphonylurea for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.
Study: NCT02197104
Drug: citocoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ten subjects will receive 1,000mg once daily of citicoline. Each subject will stay on the study drug for 12 months. The outcome measures will be assessed at baseline and then again at the end of month 3, month 6, and month 12. The subjects will continue taking the same study drug at the same dose throughout the entire trial.
Study: NCT01783015
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept placebo once-weekly
Study: NCT00873756
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT02389348
Drug: DSM265
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of DSM265